3PrimeDx, Inc. is a private, development-stage diagnostics corporation founded in 2013. We are based in Chicago, with research activities in Providence, RI. 3PrimeDx is focused on the discovery and development of novel cardiac diagnostic and theranostic tests. Our lead product is a novel, first-in-class, blood test called “PulsePredicTM” to predict risk for Sudden Cardiac Death (SCD) in individuals with heart failure. The test is based on technology developed by Dr. Samuel C. Dudley while serving as Professor and Chief of Cardiology at the University of Illinois at Chicago. Dr. Dudley is presently the Ruth and Paul Levinger Professor in Cardiology and Director at the Lifespan Cardiovascular Institute at the Warrant Alpert Medical School of Brown University.
The PulsePredicTM test measures the levels of splicing variants of a specific cardiac marker found in blood. In a cross-sectional clinical study of patients with heart failure, cardiac marker levels were shown to correlate with risk of ventricular arrhythmias – the main cause of SCD (Gao G et al; J Am Coll Cardiol 2014; 63:2261–9). 3PrimeDx is in the process of conducting additional clinical studies to further validate the PulsePredic test’s ability to predict SCD risk in individuals with heart disease.
Samuel C. Dudley, MD, PhD (Scientific Co-founder, Director, Chair of SAB)
Dr. Dudley is the Ruth and Paul Levinger Professor in Cardiology and Director at the Lifespan Cardiovascular Institute at the Warren Alpert Medical School of Brown University. He was formerly Professor and Chief of Cardiology at the University of Illinois at Chicago and principal developer of the PulsePredic™ technology. He was formerly an Associate Professor of Medicine and Physiology at Emory University and Chief of Cardiology at the Atlanta VAMC. He received his MD and PhD degrees at the Medical College of Virginia, and completed Internal Medicine and Cardiology training at the University of Chicago along with a postdoctoral fellowship in cardiac electrophysiology.
Charles Polsky, MD, Director and CEO
Dr. Polsky currently serves as a Director and Vice President of William Harris Investments, overseeing operations for WHI’s direct equity investing. Additionally, Dr. Polsky serves as a healthcare and biotechnology analyst and Co-Portfolio Manager for the WHI Growth Fund, and shares responsibility as a member of the Equity Investment Committee. Dr. Polsky holds an undergraduate degree in Mathematics from Yale University and an MD from the University of Chicago. He is boarded in Internal Medicine by The American Board of Internal Medicine.
Joel Braunstein, MD, MBA (Director, Medical Officer)
Dr. Braunstein co-founded LifeTech Research (LTR) in 2003 and is a board-certified cardiologist and internist. Dr. Braunstein has co-founded and played key operational roles in numerous life science start-ups. Dr. Braunstein received his M.D. with highest distinction from Northwestern University Medical School in 1996, trained in internal medicine at the Brigham and Women’s Hospital of Harvard University, and was a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Dr. Braunstein has maintained Adjunct Faculty positions in the Division of Cardiology at Johns Hopkins and at the Yale Center for Outcomes Research and Evaluation and Yale School of Medicine. He is a Distinguished Alumnus of Johns Hopkins University.
Micah Onixt (Operations Officer), JD, MBA
Mr. Onixt is a partner at LifeTech Research. Prior thereto, he was a partner in the Chicago office at DLA Piper and a recipient of the “40 Illinois Attorneys Under 40 to Watch” award from the Law Bulletin Publishing Company. At DLA, Mr. Onixt’s practice focused on institutional investment funds, and private and public life sciences companies in the areas of corporate securities, technology transfer (product licensing, M&A), and intellectual property management. Mr. Onixt is a current member of the American Bar Association and the American Intellectual Property Law Association. Mr. Onixt received his MBA from the Kellogg School of Management, JD from Loyola University, and undergraduate in cellular biology from the University of Michigan. Mr. Onixt is presently completing his master’s degree in molecular biology from the Illinois Institute of Technology.
Ilana Fogelman, MD, MPH (Clinical & Regulatory Affairs Officer)
Dr. Fogelman is the COO and co-founder of LifeTech Research, a venture development and medical technology due diligence company. In addition, Dr. Fogelman plays a key role in regulatory affairs in several life-sciences start-ups. From 1999 to 2003, Dr. Fogelman worked as a biotechnology analyst for Merrill Lynch and Citigroup, covering small- to mid-cap public companies. From 1993 to 1999, she worked as a medical reviewer for FDA, focusing on new products for infectious diseases, autoimmune and inflammatory disorders. Dr. Fogelman obtained her MD from the University of São Paulo (Brazil) and a Master in Public Health from Harvard University. At Harvard, she also completed two postdoctoral research fellowships in HIV clinical trials and basic immunology.